CClinicalTrials.gg
CompletedNCT04416321Updated Sep 9, 2026

A Clinical Study to Evaluate Safety and Performance of PEEK-OPTIMA™ HA Enhanced.

An interventional study of Surgery with the Keos Lumbar Interbody Fusion Device in Degenerative Disc Disease, Spondylolisthesis and Retrolisthesis, sponsored by Invibio Ltd. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-09.

Sponsored by Invibio Ltd · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this trial is to collect clinical outcomes including radiographic and CT outcomes in patients who undergo spinal fusion using the Keos Lumbar Interbody Fusion Device.

Read the detailed description

This prospective, non-comparative, single-center, post-market trial will evaluate the safety and efficacy of the PEEK-OPTIMA ™ HA Enhanced Keos Lumbar Interbody Fusion Device in patients suffering from degenerative disc disease, spondylolisthesis and retrolisthesis in the lumbar spine. The trial will capture clinical outcomes, radiographic and CT outcomes over a 24 month period post operatively. One centre will be involved in the recruitment of 30 patients the clinic involved will focus on this type of treatment.

02

Conditions studied

  • Degenerative Disc Disease
  • Spondylolisthesis
  • Retrolisthesis

Keywords

  • Lumbar Degenerative Disc Disease
  • Spondylolisthesis
  • retrolisthesis
03

In context

Intervertebral Disc Degeneration

464 studies on the registry are indexed under Intervertebral Disc Degeneration; 98 are open to participants now.

This study's enrollment of 25 is below the median of 60 across 261 interventional studies indexed under Intervertebral Disc Degeneration.

Browse Intervertebral Disc Degeneration studies →

Lead sponsor

Invibio Ltd is the lead sponsor of 6 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Aged 18 years of age or older.
  2. Primary diagnosis of symptomatic degenerative disc disease (DDD) or symptomatic degenerative disc disease (DDD) with spondylolisthesis (Grade 1), or retrolisthesis, at one or two contiguous levels from L2 to S1.
  3. Have discogenic back pain.
  4. Suitable for transforaminal lumbar interbody fusion (TLIF) surgery.
  5. Indicated for surgical treatment with the Keos Lumbar IBFD with autologous bone graft.
  6. Completed at least 6 months of conservative non-operative treatment.
  7. Female subjects of childbearing age must have a negative pregnancy test.
  8. Able to understand this clinical study, co-operate with procedures.
  9. Able to give voluntary, written informed consent to participate.

Exclusion criteria

Exclusion Criteria:

  1. Not undergone previous spinal surgery at the affected disc level(s).
  2. Evidence of tumour and/or malignant disease.
  3. Known osteoporosis or severe osteopenia.
  4. Known rheumatoid arthritis, ankylosing spondylitis or who are immunocompromised.
  5. Known allergy to the material used in the instrumentation.
  6. Evidence of an active infection.
  7. Any conditions outlined as contraindicated in the Instructions for Use.
  8. Receiving any drug treatment that may affect bone metabolism.
  9. Female subjects who are pregnant or lactating.
  10. Current smokers or have stopped smoking less than 6 months ago.
  11. Known drug or alcohol abusers.
  12. Currently enrolled in a clinical study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Other
    Device

    All subjects who are entered into this trial will receive the Keos Lumbar Interbody Fusion Device.

    Device: Surgery with the Keos Lumbar Interbody Fusion Device

Interventions

  • DeviceSurgery with the Keos Lumbar Interbody Fusion Device

    All subjects will received the Keos Lumbar Interbody Fusion Device if according to the investigators opinion they are clinically indicated to have surgery treatment for degenerative disc disease, spondylolisthesis and retrolisthesis

06

What researchers measure

Primary outcomes

  1. Interbody fusion rate

    Interbody fusion will be graded along the superior and inferior interfaces separately in 25% increments

    Time frame: 6 months post - operatively

Secondary outcomes

  1. To measure how much pain the subject is in according to a pain scale 0-10

    Visual analogue scale for back and leg 0-10 cm (no pain - worst possible pain)

    Time frame: 6 weeks, 3, 6, 12 and 24 months post operatively

  2. To measure the Quality of Life of the subject according to a set list of questions: Questionnaire SF-12

    Questionnaire SF-12 collection of questions health related to assess vitality, physical functioning, bodily pain, general health perceptions, emotional and physical functioning, social and mental health. Patients will pick from a set list of answers for each health related question. The responses on each item are scored and summarised into Physical and Mental Health Composite Scores (PCS \& MCS) and range from 0-100. The lower the score the more disability. The higher the score the less disability i.e.a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

    Time frame: pre-operatively, 6 weeks, 3, 6, 12 and 24 months post operatively

  3. Functional Impairment

    Questionnaire ODI (Oswestry Disability Index) - disability questionnaire used to assess functional impairment of the patient. Regarding lifting, ability to walk, sit, stand, sleep, travel and graded by score of 0-100 (0= no disability and 100= maximum disability possible)

    Time frame: pre-operatively, 6 weeks, 3, 6, 12 and 24 months post operatively

07

Study locations

1 site
  • Neurosurgical Associates of Lancaster
    Lancaster, Pennsylvania 17601, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04416321
Lead sponsor
Invibio Ltd
Collaborators
Keos LLC, Medical Metrics Diagnostics, Inc, Technomics Research, Viedoc Technologies
Responsible party
Sponsor
First posted
Jun 4, 2020
Start date
Jul 1, 2021
Primary completion
Jan 27, 2026
Completion
Jan 27, 2026
Last update
Sep 9, 2026

Study contacts

Louis A Marotti, M.D. PhD
principal investigator · Neurosurgical Associates of Lancaster

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion